DTV 50 Dosage/Direction for Use

DTV 50 should be prescribed by physicians experienced in the management of HIV infection.
Posology: Adults: Patients infected with HIV-1 without resistance to the integrase class: The recommended dose of DTV 50 is 50 mg (one tablet) orally once daily.
DTV 50 should be administered twice daily in this population when co-administered with some medicines (e.g. efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin).
Patients infected with HIV-1 with resistance to the integrase class: The recommended dose of DTV 50 is 50 mg (one tablet) twice daily. The decision to use dolutegravir for such patients should be informed by the integrase resistance pattern.
Co-administration of DTV 50 with some medicines should be avoided in this population (e.g. Efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin).
Adolescents aged 12 and above: In adolescents (aged from 12 to 17 years and weighing at least 40 kg) infected with HIV-1 without resistance to the integrase class, the recommended dose of DTV 50 is 50 mg once daily.
Elderly: There is no evidence that elderly patients require a different dose than younger adult patients.
Hepatic and renal impairment: No dosage adjustment is required in patients with mild, moderate or severe (CrCl <30 mL/min, not on dialysis) renal impairment.
No dosage adjustment is required in patients with mild or moderate hepatic impairment. DTV 50 should be used with caution in patients with severe hepatic impairment.
Method of administration: Oral use.
DTV 50 can be taken with or without food. In the presence of integrase class resistance, DTV 50 should preferably be taken with food to enhance exposure (particularly in patients with Q148 mutations).
If the patient misses a dose of DTV 50, the patient should take DTV 50 as soon as possible, providing the next dose is not due within 4 hours. If the next dose is due within 4 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.